Search results
Results from the WOW.Com Content Network
An assortment of Lilly's throat lozenges from a 1906 sales book Josiah K. Lilly Sr. (1861–1948), the company's second president Eli Lilly and Company's corporate headquarters in Indianapolis, c. 1919 Men and women workers preparing drug capsules at Eli Lilly and Company in 1919 Amaryllis belladonna cultivation at Eli Lilly and Company in 1919 ...
At Eli Lilly and Company, where his primary focus was marketing and human resources, he served as vice president of marketing, executive vice president of the company, and president of Eli Lilly International Corporation, before succeeded his older brother, Eli Jr., as company president in 1948 and as chairman of the board in 1953.
From 2012 to 2017, Azar was president of the U.S. division of Eli Lilly and Company, a major drug company, and a member of the board of directors of the Biotechnology Innovation Organization, a large pharmaceutical trade association. Azar served as general counsel of the U.S. Department of Health and Human Resources (HHS) from 2001 to 2005. On ...
Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving ...
Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. The ...
Unlike human GLP-1, however, exendin-4 has a half-life of several hours, making it a much better drug candidate. [14] Amylin developed exenatide, a synthetic version of exendin-4. In 2002, Eli Lilly signed an agreement with Amylin for $325 million to partner in development of exenatide. [ 16 ]
David Ricks, chair and CEO of Eli Lilly, fields a question during an announcement of the company's $3 billion expansion in Wisconsin, Thursday, Dec. 5, 2024, in Kenosha, Wis. (Sean Krajacic/The ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.